AU4124089A - Use of ACE-inhibitor for suppressing the formation of neointima and the reduction of the vascular lumen by vascular wall thickening after vascular damage - Google Patents

Use of ACE-inhibitor for suppressing the formation of neointima and the reduction of the vascular lumen by vascular wall thickening after vascular damage

Info

Publication number
AU4124089A
AU4124089A AU41240/89A AU4124089A AU4124089A AU 4124089 A AU4124089 A AU 4124089A AU 41240/89 A AU41240/89 A AU 41240/89A AU 4124089 A AU4124089 A AU 4124089A AU 4124089 A AU4124089 A AU 4124089A
Authority
AU
Australia
Prior art keywords
vascular
neointima
formation
reduction
wall thickening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU41240/89A
Other versions
AU625693B2 (en
Inventor
Hans Rudolf Baumgartner
Jean-Paul Clozel
Fridolin Hefti
Markus Hosang
Herbert Kuhn
Rita Muller
Jerry Powell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU4124089A publication Critical patent/AU4124089A/en
Application granted granted Critical
Publication of AU625693B2 publication Critical patent/AU625693B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

ACE inhibitors are able to suppress the formation of neointima and the reduction of the vessel volume owing to vessel wall thickening after a vessel injury. They are accordingly suitable for the treatment and prevention of neointima formation after vessel injury, in particular for the prevention of arterial restenosis after angioplasty or of vessel wall thickening after vascular surgery in arteries and veins.
AU41240/89A 1988-09-14 1989-09-11 Use of ace-inhibitor for suppressing the formation of neointima and the reduction of the vascular lumen by vascular wall thickening after vascular damage Ceased AU625693B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3421/88 1988-09-14
CH342188 1988-09-14

Publications (2)

Publication Number Publication Date
AU4124089A true AU4124089A (en) 1990-03-22
AU625693B2 AU625693B2 (en) 1992-07-16

Family

ID=4255625

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41240/89A Ceased AU625693B2 (en) 1988-09-14 1989-09-11 Use of ace-inhibitor for suppressing the formation of neointima and the reduction of the vascular lumen by vascular wall thickening after vascular damage

Country Status (13)

Country Link
EP (1) EP0363671B1 (en)
JP (1) JPH02121922A (en)
KR (1) KR900004337A (en)
AT (1) ATE100716T1 (en)
AU (1) AU625693B2 (en)
DE (1) DE58906814D1 (en)
DK (1) DK452089A (en)
ES (1) ES2061853T3 (en)
HU (1) HU206186B (en)
IE (1) IE892931L (en)
IL (1) IL91572A (en)
PT (1) PT91705B (en)
ZA (1) ZA896851B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3925759A1 (en) * 1989-08-03 1991-02-07 Thera Patent Verwaltungs Gmbh USE OF ACE INHIBITORS FOR ATHEROSKLEROSEPROPHYLAXE
DE3926606A1 (en) * 1989-08-11 1991-02-14 Hoechst Ag METHOD FOR THE TREATMENT OF CARDIALS AND VASCULAR HYPERTROPHY AND HYPERPLASIA
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
US5212165A (en) * 1989-10-23 1993-05-18 E. R. Squibb & Sons, Inc. Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
CA2042159A1 (en) * 1990-05-31 1991-12-01 Miguel A. Ondetti Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
EP0682947B1 (en) 1994-05-19 1997-09-10 Mitsubishi Chemical Corporation Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia
AU713530B2 (en) * 1995-03-24 1999-12-02 Molecumetics, Ltd. Beta-sheet mimetics and use thereof as protease inhibitors
KR100264807B1 (en) * 1996-01-17 2000-09-01 고바야시 유키오 Intimal hypertrophy inhibitors
EP1611886A3 (en) * 1999-08-30 2008-06-04 Sanofi-Aventis Deutschland GmbH Inhibitors of the renin-angiotensin system for the prevention of cardiovascular disorders
JP4904859B2 (en) * 2006-03-13 2012-03-28 大日本印刷株式会社 Printing unit and doctor blade polishing method
CN101478983A (en) * 2006-07-10 2009-07-08 特瓦制药工业有限公司 Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
AT377496B (en) 1981-06-19 1985-03-25 Voith Gmbh J M DEVICE FOR WINDING A TRACK OF GOODS ON A NEWLY INSERTED WRAPPING SLEEVE IN A DOUBLE-CARRIER ROLLING MACHINE

Also Published As

Publication number Publication date
JPH02121922A (en) 1990-05-09
HUT51148A (en) 1990-04-28
DK452089A (en) 1990-03-15
ES2061853T3 (en) 1994-12-16
EP0363671A2 (en) 1990-04-18
IL91572A0 (en) 1990-04-29
EP0363671B1 (en) 1994-01-26
KR900004337A (en) 1990-04-12
EP0363671A3 (en) 1991-12-11
DK452089D0 (en) 1989-09-13
AU625693B2 (en) 1992-07-16
PT91705A (en) 1990-03-30
ATE100716T1 (en) 1994-02-15
DE58906814D1 (en) 1994-03-10
HU206186B (en) 1992-09-28
IL91572A (en) 1994-01-25
ZA896851B (en) 1990-06-27
PT91705B (en) 1995-05-31
IE892931L (en) 1990-03-14

Similar Documents

Publication Publication Date Title
AU4124089A (en) Use of ACE-inhibitor for suppressing the formation of neointima and the reduction of the vascular lumen by vascular wall thickening after vascular damage
EP1649853A3 (en) Microtubule stabilizing agents for treating atherosclerosis or restenosis
DE69435137D1 (en) PREVENTION AND TREATMENT OF PATHOLOGIES ASSOCIATED WITH AN ABNORMAL PROLIFERATION GLATTER MUSCLE CELLS
EP0933995B8 (en) Method of treating endothelial injury
CA2108025A1 (en) Method for Preventing Restenosis Following Reconfiguration of Body Vessels
WO2000010552A3 (en) Use of anti-angiogenic agents for inhibiting vessel wall injury
WO2004024093A3 (en) Device and method for treating restenosis
SE8803472A (en)
CA2162587A1 (en) Therapeutic inhibitor of vascular smooth muscle cells
CA2340320A1 (en) Use of an angiogenic factor for the treatment of microascular angiopathies
AU5537994A (en) Therapeutic treatment for inhibiting vascular restenosis
WO2003032809A3 (en) Modulation of akt-dependent response to prevent restenosis
WO2001035996A3 (en) Use of pdt to inhibit intimal hyperplasia
PL335046A1 (en) Method of and agent for treating arteriosclerosis and vascular lesions by preventing proliferation of smooth muscle vascular fibres
WO1995015161A3 (en) Medicament for treating heart insufficiency
TR200501763T2 (en) Treatment and screening methods
EP1417971A3 (en) Use of an angiogenic factor for the treatment of microvascular angiopathies
CZ223199A3 (en) Use of comt inhibitors or pharmaceutically acceptable salts or esters thereof for preparing a medicament for prevention diabetic vascular dysfunctions
GB9004348D0 (en) New use of catechol derivatives and their physiologically acceptable salts and esters
GB2333964B (en) Intravenous coagulation catheter for treatment of varicose veins
UA37249C2 (en) Method for inhibiting stenosis and/or restenosis (variants), method for inhibiting restenosis upon surgery of coronary artery (variants), method for decreasing risk of non-acute ischemic complication upon reconstructive vascular surgery
UA69858A (en) Method for treating pyo-necrotic diseases of lower limbs
EP1166784A4 (en) Inhibitors for vascular reconstriction after angioplasty
Elbert et al. Endoluminal stent coatings consisting of adsorbing copolymers reduce neointimal hyperplasia in the pig
WO2004037120A3 (en) Implantable medical devices using zinc